Navigation Links
MannKind Corporation Reports Third Quarter Financial Results
Date:11/5/2008

- Conference Call Today at 9:00 a.m. EST -

VALENCIA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third quarter ended September 30, 2008.

For the third quarter of 2008, total operating expenses were $69.1 million, compared to $75.6 million for the third quarter of 2007, primarily attributable to the $9.2 million reduction in research and development (R&D) expenses which totaled $55.6 million for this quarter compared to $64.8 million for the same quarter in 2007. The decrease in R&D expenses for the three months ended September 30, 2008 as compared to the same period in the prior year was primarily due to decreased costs associated with the clinical development of AFRESA(TM) (formerly identified as the Technosphere Insulin System) and the related manufacturing costs associated with clinical trial materials, partially offset by increased stock-based compensation expense and increased facilities-related expenses. General and administrative (G&A) expenses increased by $2.7 million to $13.4 million for the third quarter of 2008 compared to the third quarter of 2007. G&A expenses for the three months ended September 30, 2008 increased as compared to the same period in the prior year primarily due to increased employee-related and consulting expenses and increased stock-based compensation expense.

For the first nine months of 2008, operating expenses totaled $224.0 million, compared to $228.3 million in the first nine months of 2007. R&D expenses for the first nine months were $181.7 million, compared to $190.1 million in 2007. The decrease in R&D expenses for the nine months ended September 30, 2008, as compared to the same period in the prior year was primarily due to decreased costs associated with the clinical development of AFRESA and the related manufacturing costs associated with clinical trial materials, partially offset by increased stock-based compensation expense and increased facilities-related expenses. G&A expenses increased by $4.2 million to $42.4 million for the first nine months of 2008 as compared to the same period in 2007. G&A expenses for the nine months ended September 30, 2008 increased as compared to the same period in the prior year primarily due to increased employee-related and consulting expenses and increased stock-based compensation expense, offset by decreased professional fees.

We anticipate that our R&D expenses associated with AFRESA will continue to decline as we close out our pivotal clinical studies and complete preparations for the filing of our New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA"). We expect G&A expenses, other than non- cash stock-based compensation expense, to remain constant in the future.

The net loss for the third quarter of 2008 was $68.5 million, or $0.67 per share, based on 101.6 million weighted average shares outstanding. This compares to a net loss of $73.0 million, or $0.99 per share, based on 73.5 million weighted average shares outstanding for the third quarter of 2007. The net loss for the first nine months of 2008 was $219.7 million, or $2.17 per share based on 101.5 million shares outstanding, compared with a net loss of $218.2 million, or $2.97 per share based on 73.4 million shares outstanding, for the first nine months of 2007.

Cash and cash equivalents and marketable securities were $95.2 million at September 30, 2008, $180.5 million at June 30, 2008, and $368.3 million at December 31, 2007.

"MannKind has made great progress this quarter," commented Alfred Mann, Chairman and Chief Executive Officer. "Our pivotal trials are completed and we are well along in preparation of the AFRESA NDA submission to the FDA. We have completed and dedicated our new manufacturing facility and equipped it with the first stage of the modular production systems that will be used to supply commercial product. The emerging data support our belief that AFRESA will be a very important prandial insulin for most people with type 1 and type 2 diabetes. We will soon be ready to reinitiate discussions with potential partners."

Conference Call

MannKind management will host a conference call to discuss these results today at 9:00 a.m. Eastern Time. To participate in the call please dial (888) 677-5721 or (210) 839-8507. To listen to the call via the Internet please visit http://www.mannkindcorp.com. The web site replay will be available for fourteen days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (866) 411-1707 or (203) 369- 0654 and entering conference number 4423761.

Presenting from the Company will be:

* Chairman and Chief Executive Officer Alfred Mann

* President and Chief Operating Officer Hakan Edstrom

* Corporate Vice President and Chief Financial Officer Matthew Pfeffer

* Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to MannKind's expected R&D and G&A expenses, clinical trials, product candidates, regulatory submissions, manufacturing facility and partnership opportunities that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials, difficulties or delays in seeking or obtaining regulatory approval, the manufacture of AFRESA, competition from other pharmaceutical or biotechnology companies, MannKind's ability to enter into any collaborations or strategic partnerships, intellectual property matters, stock price volatility and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2007 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

(Tables to follow)

MANNKIND CORPORATION

(A Development Stage Company)

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands except per share data)

Cumulative period

from February 14,

1991 (date of

Three months ended Nine months ended inception) to

September 30, September 30, September 30,

2008 2007 2008 2007 2008

Revenue $- $- $20 $10 $2,988

Operating

expenses:

Research and

development 55,645 64,825 181,665 190,093 928,705

General and

administrative 13,435 10,744 42,365 38,207 232,864

In-process

research and

development costs - - - - 19,726

Goodwill

impairment - - - - 151,428

Total operating

expenses 69,080 75,569 224,030 228,300 1,332,723

Loss from

operations (69,080) (75,569) (224,010) (228,290) (1,329,735)

Other income

(expense) (7) 62 (7) 158 (1,888)

Interest expense

on note

payable to

principal

stockholder - - - - (1,511)

Interest expense

on senior

convertible

notes (124) (778) (585) (2,824) (4,215)

Interest income 715 3,238 4,858 12,779 36,590

Loss before

provision for

income taxes (68,496) (73,047) (219,744) (218,177) (1,300,759)

Income taxes - - - - (24)

Net loss (68,496) (73,047) (219,744) (218,177) (1,300,783)

Deemed dividend

related

to beneficial

conversion

feature of

convertible

preferred stock - - - - (22,260)

Accretion on

redeemable

preferred stock - - - - (952)

Net loss

applicable to

common

stockholders $(68,496) $(73,047) $(219,744) $(218,177) $(1,323,995)

Net loss per

share

applicable to

common

stockholders -

basic and

diluted $(0.67) $(0.99) $(2.17) $(2.97)

Shares used to

compute

basic and

diluted net

loss per share

applicable

to common

stockholders 101,647 73,520 101,495 73,444

MANNKIND CORPORATION

(A Development Stage Company)

CONDENSED BALANCE SHEETS

(Unaudited)

(In thousands except share data)

September 30, December 31,

2008 2007

ASSETS

Current assets:

Cash and cash equivalents $31,582 $368,285

Marketable securities 63,651 -

State research and development credit

exchange - 831

Prepaid expenses and other current assets 7,709 9,596

Total current assets 102,942 378,712

Property and equipment - net 225,515 162,683

State research and development credit exchange

receivable - net of current portion 2,625 1,500

Other assets 550 548

Total $331,632 $543,443

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $19,992 $35,463

Accrued expenses and other current liabilities 36,087 32,095

Total current liabilities 56,079 67,558

Senior convertible notes 112,128 111,761

Other liabilities - 24

Total liabilities 168,207 179,343

Commitments and contingencies

Stockholders' equity:

Undesignated preferred stock, $0.01 par

value - 10,000,000 shares authorized; no shares

issued or outstanding at September 30, 2008 and

December 31, 2007 - -

Common stock, $0.01 par value - 150,000,000 shares

authorized; 101,710,590 and 101,380,823 shares

issued and outstanding at September 30, 2008 and

December 31, 2007, respectively 1,017 1,014

Additional paid-in capital 1,463,191 1,444,125

Deficit accumulated during the development

stage (1,300,783) (1,081,039)

Total stockholders' equity 163,425 364,100

Total $331,632 $543,443


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MannKind Corporation to Host Webcast Analyst Day September 16, 2008
2. The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
3. MannKind to Present at the Cowen and Company Healthcare Conference
4. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
5. MannKind Corporation Reports Third Quarter Financial Results
6. MannKind to Present at Upcoming Conferences
7. MannKind Announces New $350 Million Credit Facility
8. Providence Service Corporation Releases Third Quarter Results
9. United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results
10. Psychemedics Corporation Announces Third Quarter Results
11. Somanetics Corporation to Present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: